BioTech

We explore which cell therapy, genetic editing and other innovative technologies are democratizing access to and costs of healthcare, and enabling better quality of life. 

FDA Will Consider Biogen’s Controversial Drug as First New Alzheimer’s Treatment Drug in 17 Years

Karma_News Summary_Alzheimer's treatment
A controversial drug that treats the early stages of Alzheimer’s disease might become the first medication for the disease in 17 years to win regulatory approval. Biogen Inc. said it plans to submit a regulatory filing for its aducanumab...

Nebula Genomics Puts DNA on Blockchain to Buoy Privacy-Concerned Consumers

Karma_Profile_Nebula
Key Takeaway: With concerns about the privacy of genetic data rising, Nebula Genomics has developed a Blockchain-based genomic marketplace, where users decide who gets access to their data and potentially receive compensation...

Researchers Use Gene Modification to Defeat Rice-Killing Disease

Karma_News Summary_CRISPR
Researchers successfully edited the genome of strains of rice grown in Southeast Asia and West Africa to block a pathogen that ravages yields of the staple crop, the latest example of gene modification that may reduce hunger throughout the world.Bacterial blight is...

U.S. Wants More Domestic Pharma Production as Quality Concerns Persist; Lawmakers Worry About China’s Power

Karma_News Summary_Pharmaceuticals
As concerns rise about the growing percentage of U.S. drugs manufactured in China, U.S legislators are seeking measures to bring more of the industry back onshore. During a congressional hearing Wednesday, regulators and lawmakers in both parties expressed interest...

FDA Warns Medical Devices May Be Vulnerable to Hackers, Highlighting Vulnerability of Equipment to Attacks

Karma_News Analysis_Medical device cybersecurity
Pacemakers, insulin pumps and other medical devices using software called IPnet contain potential flaws that make them vulnerable to cyber attacks, the Food and Drug Administration has warned.The agency is working with medical device makers to determine which devices, whether in health-care...

Microbiome Experts Call Out Technology’s Limits, Saying it’s Still Early Days of Personalized Medicine

Karma_News Analysis_probiotics
While the number of microbiome-focused products and investments rises, the science remains in a nascent stage, and expectations for the industry may be ahead of reality, according to speakers at a Bard College symposium on Thursday. Martha Carlin, CEO...

Mouse Microbiome Study May Point to Better Human Antibiotic Tolerance

Karma_News Analysis_Microbiome
A new study into how antibiotics affect beneficial bacteria living in human guts suggests ways in which dietary changes may reduce the medicines’ side effects and generate new treatments.Brown University researchers, conducting a study in mice, found that changes in the animals’...

Bristol-Myers Partners with Accelerator BioMotiv to Develop New Drugs

test tube close up
Pharmaceutical giant Bristol-Myers Squibb will become a limited partner in BioMotiv, a Cleveland-based biotech accelerator, to jointly fund new research into therapies in disease areas with unmet medical needs.  “Partnering with an innovative accelerator like BioMotiv strengthens our ability...

Johns Hopkins to Expand Psychedelics-As-Medicine Research With $17 Million Center

large magic mushroom
Magic mushrooms as treatment for depression, PTSD other issues is getting a major boost at Johns Hopkins University, as researchers continue efforts, sometimes backed by venture capital, to find therapies in alternative, overlooked places. Johns Hopkins, which has been...

Biotech Achilles Raises $120 Million For Trials of Immune System-Harnessing Cancer Drugs

Secondary lung cancer, light micrograph
Achilles Therapeutics’s raising of $120 million to conduct clinical trials of a cancer treatment underscores the promise of therapies that use immune systems to target and eradicate tumor cells. The Achilles therapy uses a unique T-cell, a type of...

Glycomine Lands $33 Million for Trials of Therapy for Rare Genetic Disorder

Genetic Research, A human sample being pipetted into a multi well plate for genetic analysis sitting on DNA sequence
With a goal to stamp out a rare disease that takes the lives of about one-fifth of the children it affects, biotechnology company Glycomine is finding deep-pocketed support from investors including Danish pharmaceutical giant Novo Nordisk.  The San Carlos,...

Startups Using Agility, Experience, to Move the Needle on Opioid Crisis

From a social network for addicts to robots that test sewage water for traces of drugs, startups and private companies are applying innovative solutions to one of the nation’s most pressing problems -- its opioid epidemic. Over 11.4 million people have misused...

Biotech Startup Luca Mines Women’s Biome Data to Treat UT Infections, Other Health Issues

When Luca Biologics began operations this spring, it was a startup in name only, since its co-founders had been collecting laboratory data on women’s health for nearly two decades.  Armed with that research, Luca is ready to develop biotherapies...

Japan Set to Create Hybrid Mammal for Organ Donation, Unleash Ethical Storm

In a move certain to set medical ethicists’ heads spinning, stem-cell researchers in Japan are launching a study with an aim to create hybrid animals out of rats and mice that will produce human organs for medical transplant, according to media reports.

MEND Aims for Untapped Market: Better Nutrition for Surgery Patients

Life sciences start-up MEND believes better nutrition will help concussion patients before and after surgery, and is seeking to roll out another of its supplement powders to tap that market. The New York company is filing a patent for...

Musk’s Neuralink Promises Innovation But Requires Trust and Proof

While Elon Musk’s brain implant company, Neuralink, has announced plans to begin human patient tests before the end of next year, experts believe proving the technology’s competence may take longer. In an event yesterday, held primarily for recruiting more...

Vasopharm to Sell Drug for Traumatic Brain Injury, An Overlooked Killer

Germany’s Vasopharm raised $10.7 million as it plans to submit data for a clinical trial next year for its product that seeks to treat an issue with far-reaching social implications: traumatic brain injury.  Led by German PE firm HeidelbergCapital,...

BioNTech, Melding AI, Robotics and Biotech, Nets $325 Million for Vaccine Search

German start-up BioNTech raised $325 million in private funding, one of the largest hauls for a European biopharma company, which will help it develop its pipeline for cancer therapies designed to target unique characteristics of each patient’s tumor. The...

The Specter of Theranos Is Haunting Biotech Startups

The final chapter in Elizabeth Holmes’ story as an entrepreneur is set to begin next year with her fraud trial scheduled for summer of 2020. But medical device startups and investors may find the fallout from the crash and burn of her...

Biotech Startup Is Vying to Improve Memory Through Brain Implants

If Nia Therapeutics succeeds, brain chips will enter medical clinics in three years that will  provide memory generation for all patients suffering from brain injuries or disorders. Michael Kahana, a University of Pennsylvania researcher, and Dan Rizzuto, a neuroscientist,...

Russian Scientist Plans Gene-Edited Baby Following Chinese Experiment

On Our Radar: Deals we are paying attention to, for their impact on industry Russian scientist Denis Rebrikov told Nature he’s planning the same experiment a Chinese scientist did last year that the rest of the world is more...

Whole Biome’s Latest Round Shows Investor Appetite for Probiotics

A handful of biotech companies are pursuing the development of microbiome drugs, and many prominent investors are placing their bets. With $35 million series B funding led by Sequoia Capital, Whole Biome is on track to start selling a capsule...

From Fertility to Fintech, Chiratae Ventures Tackles India’s Big Problems

Strategic Investors: Profiles of investors with strategies to consider. Chiratae Ventures has made a name for itself in India’s fast-growing venture capital scene with investments focused on innovative consumer tech, health and online retail. But the fund, part of the global IDG Ventures family, has...

Poseida CEO Eric Ostertag on Standing Out in Crowded Biotech Field

Sound Businesses: Profiles of companies and business models we are keeping an eye on. It’s been an interesting year for Poseida Therapeutics, the human therapeutics company that spun out of Transposagen Biopharmaceuticals in 2015. Poseida in January filed for an IPO, only to have it...

Ancestry’s IPO Talk Shows How Consumer DNA Testing Has Matured

Surging popularity of home DNA kits that enable consumers to uncover secrets of their ancestry and health risks has fueled speculation that the industry is set for further disruption this year. Ancestry.com, the world’s largest direct-to-consumer genetic-testing company, is getting ready for an initial public...

Ancestry’s IPO Talk Shows How Consumer DNA Testing Has Matured

Surging popularity of home DNA kits that enable consumers to uncover secrets of their ancestry and health risks has fueled speculation that the industry is set for further disruption this year. Ancestry.com, the world’s largest direct-to-consumer genetic-testing company, is getting ready for an initial public...

Hefty Funding Rounds for Three Companies Highlight the Potential of AI in Healthcare

On Our Radar: Deals we are paying attention to, for their impact on industry. It was a good day for artificial intelligence companies in the healthcare space. A very good day. Within hours on Wednesday, three firms developing AI-based platforms, PathAI, Bardy Diagnostics and Aidoc, announced separate...

TA Associates Acquires Stake in Indian Fertility Hospital Chain

On Our Radar: Deals we are paying attention to for their impact on industry. Private equity firm TA Associates acquired a minority stake in Indira IVF, a leading fertility hospital chain in India. The Boston-based TA Associates said its investment will go into growing the infertility treatment provider...

Hatteras Venture Plans to Fund Life Science Startups With New Fund

On Our Radar: Deals we are paying attention to for their impact on industry. Venture capital firm Hatteras Venture Partners raised $94 million for its sixth fund, HVP VI, with plans to hit $200 million for investments in life science startups. Hatteras should reach its $200...

CMS Medical Buys 25% of Midatech’s Outstanding Stock

On Our Radar: Deals we are paying attention to for their impact on industry. CMS Medical Venture Investment has bought a quarter of Midatech Pharma Plc’s stock outstanding, reported Bloomberg on April 8. Both are specialty pharmaceutical companies, with CMS owned by a holding company. The venture...
- Advertisement -